6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
greater O
than O
placebo O
listed O
in O
descending O
order O
of O
frequency O
) O
: O
upper O
respiratory O
infection O
, O
fever O
, O
headache O
, O
pharyngitis O
, O
cough O
, O
abdominal O
pain O
, O
diarrhea O
, O
otitis O
media O
, O
influenza O
, O
rhinorrhea O
, O
sinusitis O
, O
otitis O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Merck O
Sharp O
& O
Dohme O
Corp. O
, O
a O
subsidiary O
of O
Merck O
& O
Co. O
, O
Inc. O
, O
at O
1-877-888-4231 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

In O
the O
following O
description O
of O
clinical O
trials O
experience O
, O
adverse O
reactions O
are O
listed O
regardless O
of O
causality O
assessment O
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
greater O
than O
placebo O
; O
listed O
in O
descending O
order O
of O
frequency O
) O
in O
controlled O
clinical O
trials O
were O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
rhinorrhea B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
. O

Adults O
and O
Adolescents O
15 O
Years O
of O
Age O
and O
Older O
with O
Asthma O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
approximately O
2950 O
adult O
and O
adolescent O
patients O
15 O
years O
of O
age O
and O
older O
in O
clinical O
trials O
. O

In O
placebo-controlled O
clinical O
trials O
, O
the O
following O
adverse O
experiences O
reported O
with O
SINGULAIR O
occurred O
in O
greater O
than O
or O
equal O
to O
1 O
% O
of O
patients O
and O
at O
an O
incidence O
greater O
than O
that O
in O
patients O
treated O
with O
placebo O
: O
Table O
1 O
: O
Adverse O
Experiences O
Occurring O
in O
> O
=1 O
% O
of O
Patients O
with O
an O
Incidence O
Greater O
than O
that O
in O
Patients O
Treated O
with O
Placebo O
SINGULAIR O
10 O
mg/day O
( O
% O
) O
( O
n=1955 O
) O
Placebo O
( O
% O
) O
( O
n=1180 O
) O
Body B-NonOSE_AE
As I-NonOSE_AE
A I-NonOSE_AE
Whole I-NonOSE_AE
Pain B-OSE_Labeled_AE
, O
abdominal I-OSE_Labeled_AE
Asthenia B-OSE_Labeled_AE
/ O
fatigue B-OSE_Labeled_AE
Fever B-OSE_Labeled_AE
Trauma B-OSE_Labeled_AE
2.91.81.51.0 O
2.51.20.90.8 O
Digestive B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Dyspepsia B-OSE_Labeled_AE
Pain B-OSE_Labeled_AE
, O
dental I-OSE_Labeled_AE
Gastroenteritis B-OSE_Labeled_AE
, O
infectious I-OSE_Labeled_AE
2.11.71.5 O
1.11.00.5 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
/ I-NonOSE_AE
Psychiatric I-NonOSE_AE
Headache B-OSE_Labeled_AE
Dizziness B-OSE_Labeled_AE
18.41.9 O
18.11.4 O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Influenza B-OSE_Labeled_AE
Cough B-OSE_Labeled_AE
Congestion B-OSE_Labeled_AE
, O
nasal I-OSE_Labeled_AE
4.22.71.6 O
3.92.41.3 O
Skin B-NonOSE_AE
/ I-NonOSE_AE
Skin I-NonOSE_AE
Appendages I-NonOSE_AE
Disorder I-NonOSE_AE
Rash B-OSE_Labeled_AE
1.6 O
1.2 O
Laboratory B-NonOSE_AE
Adverse I-NonOSE_AE
Experiences I-NonOSE_AE
[ O
note O
: O
Number O
of O
patients O
tested O
( O
SINGULAIR O
and O
placebo O
, O
respectively O
) O
: O
ALT O
and O
AST O
, O
1935 O
, O
1170 O
; O
pyuria B-OSE_Labeled_AE
, O
1924 O
, O
1159 O
. O
] O

ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Pyuria B-OSE_Labeled_AE
2.11.61.0 O
2.01.20.9 O
The O
frequency O
of O
less O
common O
adverse O
events O
was O
comparable O
between O
SINGULAIR O
and O
placebo O
. O

The O
safety O
profile O
of O
SINGULAIR O
, O
when O
administered O
as O
a O
single O
dose O
for O
prevention O
of O
EIB B-Not_AE_Candidate
in O
adult O
and O
adolescent O
patients O
15 O
years O
of O
age O
and O
older O
, O
was O
consistent O
with O
the O
safety O
profile O
previously O
described O
for O
SINGULAIR O
. O

Cumulatively O
, O
569 O
patients O
were O
treated O
with O
SINGULAIR O
for O
at O
least O
6 O
months O
, O
480 O
for O
one O
year O
, O
and O
49 O
for O
two O
years O
in O
clinical O
trials O
. O

With O
prolonged O
treatment O
, O
the O
adverse O
experience O
profile O
did O
not O
significantly O
change O
. O

Pediatric O
Patients O
6 O
to O
14 O
Years O
of O
Age O
with O
Asthma O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
476 O
pediatric O
patients O
6 O
to O
14 O
years O
of O
age O
. O

Cumulatively O
, O
289 O
pediatric O
patients O
were O
treated O
with O
SINGULAIR O
for O
at O
least O
6 O
months O
, O
and O
241 O
for O
one O
year O
or O
longer O
in O
clinical O
trials O
. O

The O
safety O
profile O
of O
SINGULAIR O
in O
the O
8-week O
, O
double-blind O
, O
pediatric O
efficacy O
trial O
was O
generally O
similar O
to O
the O
adult O
safety O
profile O
. O

In O
pediatric O
patients O
6 O
to O
14 O
years O
of O
age O
receiving O
SINGULAIR O
, O
the O
following O
events O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
more O
frequently O
than O
in O
pediatric O
patients O
who O
received O
placebo O
: O
pharyngitis B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
laryngitis B-OSE_Labeled_AE
. O

The O
frequency O
of O
less O
common O
adverse O
events O
was O
comparable O
between O
SINGULAIR O
and O
placebo O
. O

With O
prolonged O
treatment O
, O
the O
adverse O
experience O
profile O
did O
not O
significantly O
change O
. O

The O
safety O
profile O
of O
SINGULAIR O
, O
when O
administered O
as O
a O
single O
dose O
for O
prevention O
of O
EIB B-Not_AE_Candidate
in O
pediatric O
patients O
6 O
years O
of O
age O
and O
older O
, O
was O
consistent O
with O
the O
safety O
profile O
previously O
described O
for O
SINGULAIR O
. O

In O
studies O
evaluating O
growth O
rate O
, O
the O
safety O
profile O
in O
these O
pediatric O
patients O
was O
consistent O
with O
the O
safety O
profile O
previously O
described O
for O
SINGULAIR O
. O

In O
a O
56-week O
, O
double-blind O
study O
evaluating O
growth O
rate O
in O
pediatric O
patients O
6 O
to O
8 O
years O
of O
age O
receiving O
SINGULAIR O
, O
the O
following O
events O
not O
previously O
observed O
with O
the O
use O
of O
SINGULAIR O
in O
this O
age O
group O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
more O
frequently O
than O
in O
pediatric O
patients O
who O
received O
placebo O
: O
headache B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
( I-OSE_Labeled_AE
infective I-OSE_Labeled_AE
) O
, O
varicella B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
atopic B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
bronchitis I-OSE_Labeled_AE
, O
tooth B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
myopia B-OSE_Labeled_AE
. O

Pediatric O
Patients O
2 O
to O
5 O
Years O
of O
Age O
with O
Asthma O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
573 O
pediatric O
patients O
2 O
to O
5 O
years O
of O
age O
in O
single- O
and O
multiple-dose O
studies O
. O

Cumulatively O
, O
426 O
pediatric O
patients O
2 O
to O
5 O
years O
of O
age O
were O
treated O
with O
SINGULAIR O
for O
at O
least O
3 O
months O
, O
230 O
for O
6 O
months O
or O
longer O
, O
and O
63 O
patients O
for O
one O
year O
or O
longer O
in O
clinical O
trials O
. O

In O
pediatric O
patients O
2 O
to O
5 O
years O
of O
age O
receiving O
SINGULAIR O
, O
the O
following O
events O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
more O
frequently O
than O
in O
pediatric O
patients O
who O
received O
placebo O
: O
fever B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
rhinorrhea B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
varicella B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
and O
conjunctivitis B-OSE_Labeled_AE
. O

Pediatric O
Patients O
6 O
to O
23 O
Months O
of O
Age O
with O
Asthma O
Safety O
and O
effectiveness O
in O
pediatric O
patients O
younger O
than O
12 O
months O
of O
age O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
175 O
pediatric O
patients O
6 O
to O
23 O
months O
of O
age O
. O

The O
safety O
profile O
of O
SINGULAIR O
in O
a O
6-week O
, O
double-blind O
, O
placebo-controlled O
clinical O
study O
was O
generally O
similar O
to O
the O
safety O
profile O
in O
adults O
and O
pediatric O
patients O
2 O
to O
14 O
years O
of O
age O
. O

In O
pediatric O
patients O
6 O
to O
23 O
months O
of O
age O
receiving O
SINGULAIR O
, O
the O
following O
events O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
more O
frequently O
than O
in O
pediatric O
patients O
who O
received O
placebo O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
wheezing B-OSE_Labeled_AE
; O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
; O
pharyngitis B-OSE_Labeled_AE
, O
tonsillitis B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
; O
and O
rhinitis B-OSE_Labeled_AE
. O

The O
frequency O
of O
less O
common O
adverse O
events O
was O
comparable O
between O
SINGULAIR O
and O
placebo O
. O

Adults O
and O
Adolescents O
15 O
Years O
of O
Age O
and O
Older O
with O
Seasonal O
Allergic O
Rhinitis O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
2199 O
adult O
and O
adolescent O
patients O
15 O
years O
of O
age O
and O
older O
in O
clinical O
trials O
. O

SINGULAIR O
administered O
once O
daily O
in O
the O
morning O
or O
in O
the O
evening O
had O
a O
safety O
profile O
similar O
to O
that O
of O
placebo O
. O

In O
placebo-controlled O
clinical O
trials O
, O
the O
following O
event O
was O
reported O
with O
SINGULAIR O
with O
a O
frequency O
> O
=1 O
% O
and O
at O
an O
incidence O
greater O
than O
placebo O
: O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
1.9 O
% O
of O
patients O
receiving O
SINGULAIR O
vs O
. O
1.5 O
% O
of O
patients O
receiving O
placebo O
. O

In O
a O
4-week O
, O
placebo-controlled O
clinical O
study O
, O
the O
safety O
profile O
was O
consistent O
with O
that O
observed O
in O
2-week O
studies O
. O

The O
incidence O
of O
somnolence B-NonOSE_AE
was O
similar O
to O
that O
of O
placebo O
in O
all O
studies O
. O

Pediatric O
Patients O
2 O
to O
14 O
Years O
of O
Age O
with O
Seasonal O
Allergic O
Rhinitis O
SINGULAIR O
has O
been O
evaluated O
in O
280 O
pediatric O
patients O
2 O
to O
14 O
years O
of O
age O
in O
a O
2-week O
, O
multicenter O
, O
double-blind O
, O
placebo-controlled O
, O
parallel-group O
safety O
study O
. O

SINGULAIR O
administered O
once O
daily O
in O
the O
evening O
had O
a O
safety O
profile O
similar O
to O
that O
of O
placebo O
. O

In O
this O
study O
, O
the O
following O
events O
occurred O
with O
a O
frequency O
> O
=2 O
% O
and O
at O
an O
incidence O
greater O
than O
placebo O
: O
headache B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
and O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Adults O
and O
Adolescents O
15 O
Years O
of O
Age O
and O
Older O
with O
Perennial O
Allergic O
Rhinitis O
SINGULAIR O
has O
been O
evaluated O
for O
safety O
in O
3357 O
adult O
and O
adolescent O
patients O
15 O
years O
of O
age O
and O
older O
with O
perennial B-Not_AE_Candidate
allergic I-Not_AE_Candidate
rhinitis I-Not_AE_Candidate
of O
whom O
1632 O
received O
SINGULAIR O
in O
two O
, O
6-week O
, O
clinical O
studies O
. O

SINGULAIR O
administered O
once O
daily O
had O
a O
safety O
profile O
consistent O
with O
that O
observed O
in O
patients O
with O
seasonal B-Not_AE_Candidate
allergic I-Not_AE_Candidate
rhinitis I-Not_AE_Candidate
and O
similar O
to O
that O
of O
placebo O
. O

In O
these O
two O
studies O
, O
the O
following O
events O
were O
reported O
with O
SINGULAIR O
with O
a O
frequency O
> O
=1 O
% O
and O
at O
an O
incidence O
greater O
than O
placebo O
: O
sinusitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
sinus B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
. O

The O
incidence O
of O
somnolence B-NonOSE_AE
was O
similar O
to O
that O
of O
placebo O
. O

Pediatric O
Patients O
6 O
Months O
to O
14 O
Years O
of O
Age O
with O
Perennial O
Allergic O
Rhinitis O
The O
safety O
in O
patients O
2 O
to O
14 O
years O
of O
age O
with O
perennial B-Not_AE_Candidate
allergic I-Not_AE_Candidate
rhinitis I-Not_AE_Candidate
is O
supported O
by O
the O
safety O
in O
patients O
2 O
to O
14 O
years O
of O
age O
with O
seasonal B-Not_AE_Candidate
allergic I-Not_AE_Candidate
rhinitis I-Not_AE_Candidate
. O

The O
safety O
in O
patients O
6 O
to O
23 O
months O
of O
age O
is O
supported O
by O
data O
from O
pharmacokinetic O
and O
safety O
and O
efficacy O
studies O
in O
asthma B-Not_AE_Candidate
in O
this O
pediatric O
population O
and O
from O
adult O
pharmacokinetic O
studies O
. O

6.2 O
Post-Marketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
SINGULAIR O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
increased B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
tendency I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylaxis B-OSE_Labeled_AE
, O
hepatic B-OSE_Labeled_AE
eosinophilic I-OSE_Labeled_AE
infiltration I-OSE_Labeled_AE
. O

Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
agitation B-OSE_Labeled_AE
including O
aggressive B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
or O
hostility B-OSE_Labeled_AE
, O
anxiousness B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
disorientation B-OSE_Labeled_AE
, O
disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
, O
dream B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
restlessness B-OSE_Labeled_AE
, O
somnambulism B-OSE_Labeled_AE
, O
suicidal B-OSE_Labeled_AE
thinking O
and O
behavior I-OSE_Labeled_AE
( O
including O
suicide B-OSE_Labeled_AE
) O
, O
tic B-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
drowsiness B-OSE_Labeled_AE
, O
paraesthesia B-OSE_Labeled_AE
/ O
hypoesthesia B-OSE_Labeled_AE
, O
seizures B-OSE_Labeled_AE
. O

Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
palpitations B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
epistaxis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
diarrhea B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
. O

Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Cases O
of O
cholestatic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
hepatocellular B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
- I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
and O
mixed B-OSE_Labeled_AE
- I-OSE_Labeled_AE
pattern I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
SINGULAIR O
. O

Most O
of O
these O
occurred O
in O
combination O
with O
other O
confounding O
factors O
, O
such O
as O
use O
of O
other O
medications O
, O
or O
when O
SINGULAIR O
was O
administered O
to O
patients O
who O
had O
underlying O
potential O
for O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
such O
as O
alcohol O
use O
or O
other O
forms O
of O
hepatitis B-Not_AE_Candidate
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
angioedema B-OSE_Labeled_AE
, O
bruising B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
nodosum I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
/ O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
arthralgia B-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
including O
muscle B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
. O

Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
: O
enuresis B-OSE_Labeled_AE
in O
children O
. O

General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
: O
edema B-OSE_Labeled_AE
. O

Patients O
with O
asthma B-Not_AE_Candidate
on O
therapy O
with O
SINGULAIR O
may O
present O
with O
systemic B-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
, O
sometimes O
presenting O
with O
clinical O
features O
of O
vasculitis B-OSE_Labeled_AE
consistent O
with O
Churg B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Strauss I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
a O
condition O
which O
is O
often O
treated O
with O
systemic O
corticosteroid O
therapy O
. O

These O
events O
have O
been O
sometimes O
associated O
with O
the O
reduction O
of O
oral O
corticosteroid O
therapy O
. O

Physicians O
should O
be O
alert O
to O
eosinophilia B-NonOSE_AE
, O
vasculitic B-NonOSE_AE
rash I-NonOSE_AE
, O
worsening B-NonOSE_AE
pulmonary I-NonOSE_AE
symptoms I-NonOSE_AE
, O
cardiac B-NonOSE_AE
complications I-NonOSE_AE
, O
and/or O
neuropathy B-NonOSE_AE
presenting O
in O
their O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

